128 related articles for article (PubMed ID: 25245988)
21. Exploring binding sites other than the catalytic core in the crystal structure of the catalytic domain of MKP-4.
Jeong DG; Yoon TS; Jung SK; Park BC; Park H; Ryu SE; Kim SJ
Acta Crystallogr D Biol Crystallogr; 2011 Jan; 67(Pt 1):25-31. PubMed ID: 21206059
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
[TBL] [Abstract][Full Text] [Related]
23. Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.
Bakan A; Lazo JS; Wipf P; Brummond KM; Bahar I
Curr Med Chem; 2008; 15(25):2536-44. PubMed ID: 18855677
[TBL] [Abstract][Full Text] [Related]
24. Identification of inhibitors that target dual-specificity phosphatase 5 provide new insights into the binding requirements for the two phosphate pockets.
Neumann TS; Span EA; Kalous KS; Bongard R; Gastonguay A; Lepley MA; Kutty RG; Nayak J; Bohl C; Lange RG; Sarker MI; Talipov MR; Rathore R; Ramchandran R; Sem DS
BMC Biochem; 2015 Aug; 16():19. PubMed ID: 26286528
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.
Park H; Jung SK; Jeong DG; Ryu SE; Kim SJ
Bioorg Med Chem Lett; 2008 Apr; 18(7):2250-5. PubMed ID: 18358718
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Seo H; Cho S
Pharmazie; 2016 Apr; 71(4):196-200. PubMed ID: 27209699
[TBL] [Abstract][Full Text] [Related]
27. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26).
Song M; Park JE; Park SG; Lee DH; Choi HK; Park BC; Ryu SE; Kim JH; Cho S
Biochem Biophys Res Commun; 2009 Apr; 381(4):491-5. PubMed ID: 19233143
[TBL] [Abstract][Full Text] [Related]
28. Structure-based de novo design of Eya2 phosphatase inhibitors.
Park H; Ryu SE; Kim SJ
J Mol Graph Model; 2012 Sep; 38():382-8. PubMed ID: 23085179
[TBL] [Abstract][Full Text] [Related]
29. A conserved motif in JNK/p38-specific MAPK phosphatases as a determinant for JNK1 recognition and inactivation.
Liu X; Zhang CS; Lu C; Lin SC; Wu JW; Wang ZX
Nat Commun; 2016 Mar; 7():10879. PubMed ID: 26988444
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of a novel mitogen-activated protein kinase phosphatase, SKRP1.
Wei CH; Ryu SY; Jeon YH; Yoon MY; Jeong DG; Kim SJ; Ryu SE
Proteins; 2011 Nov; 79(11):3242-6. PubMed ID: 21989941
[No Abstract] [Full Text] [Related]
31. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
Park H; Bahn YJ; Ryu SE
Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
[TBL] [Abstract][Full Text] [Related]
32. Structural Insight into the Critical Role of the N-Terminal Region in the Catalytic Activity of Dual-Specificity Phosphatase 26.
Won EY; Lee SO; Lee DH; Lee D; Bae KH; Lee SC; Kim SJ; Chi SW
PLoS One; 2016; 11(9):e0162115. PubMed ID: 27583453
[TBL] [Abstract][Full Text] [Related]
33. Toward the virtual screening of Cdc25A phosphatase inhibitors with the homology modeled protein structure.
Park H; Jeon YH
J Mol Model; 2008 Sep; 14(9):833-41. PubMed ID: 18504625
[TBL] [Abstract][Full Text] [Related]
34. Dual Specificity Phosphatase 5-Substrate Interaction: A Mechanistic Perspective.
Kutty RG; Talipov MR; Bongard RD; Lipinski RAJ; Sweeney NL; Sem DS; Rathore R; Ramchandran R
Compr Physiol; 2017 Sep; 7(4):1449-1461. PubMed ID: 28915331
[TBL] [Abstract][Full Text] [Related]
35. High-resolution crystal structure of the catalytic domain of human dual-specificity phosphatase 26.
Won EY; Xie Y; Takemoto C; Chen L; Liu ZJ; Wang BC; Lee D; Woo EJ; Park SG; Shirouzu M; Yokoyama S; Kim SJ; Chi SW
Acta Crystallogr D Biol Crystallogr; 2013 Jun; 69(Pt 6):1160-70. PubMed ID: 23695260
[TBL] [Abstract][Full Text] [Related]
36. PTP inhibitor IV protects JNK kinase activity by inhibiting dual-specificity phosphatase 14 (DUSP14).
Park JE; Park BC; Song M; Park SG; Lee DH; Park SY; Kim JH; Cho S
Biochem Biophys Res Commun; 2009 Oct; 387(4):795-9. PubMed ID: 19646420
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel PARP-1 inhibitors by structure-based virtual screening.
Hannigan K; Kulkarni SS; Bdzhola VG; Golub AG; Yarmoluk SM; Talele TT
Bioorg Med Chem Lett; 2013 Nov; 23(21):5790-4. PubMed ID: 24074844
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
Park H; Choi H; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
[TBL] [Abstract][Full Text] [Related]
39. The family-wide structure and function of human dual-specificity protein phosphatases.
Jeong DG; Wei CH; Ku B; Jeon TJ; Chien PN; Kim JK; Park SY; Hwang HS; Ryu SY; Park H; Kim DS; Kim SJ; Ryu SE
Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):421-35. PubMed ID: 24531476
[TBL] [Abstract][Full Text] [Related]
40. Three-dimensional docking in the MAPK p38α.
Goldsmith EJ
Sci Signal; 2011 Dec; 4(204):pe47. PubMed ID: 22375047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
